PI：周虎教授博士生导师
个人简历：
1996年毕业于安徽大学生物系，获生物化学学士学位；2001年毕业于徐州医学院，获生物化学与分子生物学硕士学位；2005年毕业于清华大学生物科学与技术系，获生物学博士学位；2005年至2011年在美国Sanford-Burnham-Prebys医学研究所从事博士后研究；2011年至2012年任厦门大学药学院副教授；2012年至今任厦门大学药学院教授。主要从事细胞信号转导，核受体，以及小分子药物的研究。论文发表在Science, Cancer Cell, Nature Communications, Acta Pharmaceutica Sinica B, Cell Reports, Cancer Research, Cancer Letters, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Journal of Natural Products, Molecular Pharmaceutics等科学期刊。研究成果获得2004年度教育部“中国高等学校十大科技进展”。2012年入选“教育部新世纪优秀人才支持计划”。
实验室简介
本实验室主要开展以下研究内容：以细胞信号转导和核受体为研究对象，探寻肿瘤及其他疾病发生发展过程中的分子变化方式、程序和机制；研究一些疾病之间的相互关联方式和转化机制，如炎症与肿瘤，并且寻找潜在的治疗靶点和方法；寻找新的核受体调节配体分子和细胞信号转导调控分子，揭示新的药物作用靶点；通过计算机模拟和有机合成等方法，对先导化合物进行优化，开发新型靶点药物。
目前开展的工作
1.核受体与细胞信号转导的相互作用；
2.天然和人工合成的核受体配体；
3.核受体的翻译后修饰及其功能；
4.核受体与信号转导对自噬等细胞生理活动的调控；
5.核受体与信号转导对肿瘤生长和炎症反应的调节；
6.计算机辅助药物的设计与优化；
7.先导化合物的优化。
代表性论文：
1: Ye F, Yuan Z, Tang Y, Li J, Liu X, Sun X, Chen S, Ye X, Zeng Z, Zhang XK, Zhou H*. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion. Cell Rep. 2024 Mar 27;43(4):114002. doi: 10.1016/j.celrep.2024.114002. Epub ahead of print. PMID: 38547126. (* corresponding author)
2: Qin J, Niu B, Chen X, Hu C, Lu S, Li H, Liu W, Li J, Teng Z, Yang Y, Hu H, Xu Y, Huo S, Wu Z, Qiu Y*, Zhou H*, Fang M*. Discovery of 5-(Pyrimidin-2-ylamino)-1H-indole-2-carboxamide Derivatives as Nur77 Modulators with Selective and Potent Activity Against Triple-Negative Breast Cancer. J Med Chem. 2023 Dec 14;66(23):15847-15866. doi: 10.1021/acs.jmedchem.3c01336. Epub 2023 Nov 20. PMID: 37983615. (* co-corresponding authors)
3: Niu B, Wu Y, Zhou M, Lin R, Ge P, Chen X, Zhou H*, Zhang X, Xie J*. Precise delivery of celastrol by PEGylated aptamer dendrimer nanoconjugates for enormous therapeutic effect via superior intratumor penetration over antibody counterparts. Cancer Lett. 2023 Nov 28;579:216461. doi: 10.1016/j.canlet.2023.216461. Epub 2023 Oct 26. PMID: 37898358. (* co-corresponding authors)
4: Ye X, Yang Y, Yao J, Wang M, Liu Y, Xie G, Zeng Z, Zhang XK, Zhou H*. Nuclear receptor RXRα binds the precursor of miR-103 to inhibit its maturation. BMC Biol. 2023 Sep 21;21(1):197. doi: 10.1186/s12915-023-01701-3. PMID: 37735649; PMCID: PMC10512521. (* corresponding author)
5: Liu J, Gao S, Zhou W, Chen Y, Wang Z, Zeng Z, Zhou H*, Lin T*. Dihydrotrichodimerol Purified from the Marine Fungus Acremonium citrinum Prevents NAFLD by Targeting PPARα. J Nat Prod. 2023 May 26;86(5):1189-1201. doi: 10.1021/acs.jnatprod.2c00990. Epub 2023 Apr 21. PMID: 37083418. (* co-corresponding authors)
6: Chen J, Zhang Y, Zeng D, Zhang B, Ye X, Zeng Z, Zhang XK, Wang Z*, Zhou H*. Merbromin is a mixed-type inhibitor of 3-chyomotrypsin like protease of SARS-CoV-2. Biochem Biophys Res Commun. 2022 Feb 5;591:118-123. doi: 10.1016/j.bbrc.2021.12.108. Epub 2021 Dec 30. PMID: 35007835; PMCID: PMC8716398. (* co-corresponding authors)
7: Huang F, Zeng Z, Zhang W, Yan Z, Chen J, Yu L, Yang Q, Li Y, Yu H, Chen J, Wu C, Zhang XK, Su Y*, Zhou H*. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy. Eur J Med Chem. 2021 Oct 15;222:113542. doi: 10.1016/j.ejmech.2021.113542. Epub 2021 May 24. PMID: 34118723. (* co-corresponding authors)
8: Niu B, Liu J, Lv B, Lin J, Li X, Wu C, Jiang X, Zeng Z, Zhang XK, Zhou H*. Interplay between transforming growth factor-β and Nur77 in dual regulations of inhibitor of differentiation 1 for colonic tumorigenesis. Nat Commun. 2021 May 14;12(1):2809. doi: 10.1038/s41467-021-23048-5. PMID: 33990575; PMCID: PMC8121807. (* corresponding author)
9: Wang K, Chen Y, Gao S, Wang M, Ge M, Yang Q, Liao M, Xu L, Chen J, Zeng Z, Chen H, Zhang XK, Lin T*, Zhou H*. Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ERα to inhibit RANKL signaling. Acta Pharm Sin B. 2021 Feb;11(2):442-455. doi: 10.1016/j.apsb.2020.09.012. Epub 2020 Sep 28. PMID: 33643823; PMCID: PMC7893202. (* co-corresponding authors)
10: Lin T, Yang Y, Ye X, Yao J, Zhou H*. Low expression of miR-99b promotes progression of clear cell renal cell carcinoma by up-regulating IGF1R/Akt/mTOR signaling. Int J Clin Exp Pathol. 2020 Dec 1;13(12):3083-3091. PMID: 33425108; PMCID: PMC7791382. (* corresponding author)
11: Huang F, Li Y, Chen J, Zhang XK, Zhou H*. Rosiglitazone binds to RXRα to induce RXRα tetramerization and NB4 cell differentiation. Biochem Biophys Res Commun. 2020 Sep 10;530(1):160-166. doi: 10.1016/j.bbrc.2020.06.134. Epub 2020 Jul 30. PMID: 32828280. (* corresponding author)
12: Qin J, Liu J, Wu C, Xu J, Tang B, Guo K, Chen X, Liu W, Wu T, Zhou H*, Fang M*, Wu Z*. Synthesis and biological evaluation of (3/4-(pyrimidin-2-ylamino)benzoyl)-based hydrazine-1-carboxamide/carbothioamide derivatives as novel RXRα antagonists. J Enzyme Inhib Med Chem. 2020 Dec;35(1):880-896. doi: 10.1080/14756366.2020.1740692. PMID: 32223461; PMCID: PMC7170311. (* co-corresponding authors)
13: Zhang S, Gao W, Tang J, Zhang H, Zhou Y, Liu J, Chen K, Liu F, Li W, To SKY, Wong AST, Zhang XK, Zhou H*, Zeng JZ*. The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma. Theranostics. 2020 Jan 1;10(3):1230-1244. doi: 10.7150/thno.38711. PMID: 31938062; PMCID: PMC6956800. (* co-corresponding authors)
14: Ye F, Chen S, Liu X, Ye X, Wang K, Zeng Z, Su Y, Zhang XK*, Zhou H*. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation. J Cell Mol Med. 2019 Jan;23(1):155-166. doi: 10.1111/jcmm.13900. Epub 2018 Oct 28. PMID: 30370662; PMCID: PMC6307790. (* co-corresponding authors)
15: Ren G, Bao W, Zeng Z, Zhang W, Shang C, Wang M, Su Y, Zhang XK, Zhou H*. Retinoid X Receptor Alpha Nitro-ligand Z-10 and Its Optimized Derivative Z-36 Reduce β-Amyloid Plaques in Alzheimer's Disease Mouse Model. Mol Pharm. 2019 Feb 4;16(2):480-488. doi: 10.1021/acs.molpharmaceut.8b00096. Epub 2018 Dec 31. PMID: 29995422. (* corresponding author)
16: Xu L, Zeng Z, Zhang W, Ren G, Ling X, Huang F, Xie P, Su Y, Zhang XK*, Zhou H*. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner. Oncotarget. 2017 Feb 14;8(7):12311-12322. doi: 10.18632/oncotarget.14812. PMID: 28129653; PMCID: PMC5355346. (* co-corresponding authors)
17: Chen F, Chen J, Lin J, Cheltsov AV, Xu L, Chen Y, Zeng Z, Chen L, Huang M, Hu M, Ye X, Zhou Y, Wang G, Su Y, Zhang L, Zhou F, Zhang XK*, Zhou H*. NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cell. Protein & Cell. 2015 Sep;6(9):654-666. doi: 10.1007/s13238-015-0178-9. Epub 2015 Jul 9. PMID: 26156677; PMCID: PMC4537469. (* co-corresponding authors)
18: Zeng Z, Sun Z, Huang M, Zhang W, Liu J, Chen L, Chen F, Zhou Y, Lin J, Huang F, Xu L, Zhuang Z, Guo S, Alitongbieke G, Xie G, Xu Y, Lin B, Cao X, Su Y, Zhang XK*, Zhou H*. Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB. Cancer Res. 2015 May 15;75(10):2049-60. doi: 10.1158/0008-5472.CAN-14-2435. Epub 2015 Mar 20. PMID: 25795708; PMCID: PMC4433622. (* co-corresponding authors)
19: Gao W, Liu J, Hu M, Huang M, Cai S, Zeng Z, Lin B, Cao X, Chen J, Zeng JZ, Zhou H*, Zhang XK*. Regulation of proteolytic cleavage of retinoid X receptor-α by GSK-3β. Carcinogenesis. 2013 Jun;34(6):1208-15. doi: 10.1093/carcin/bgt043. Epub 2013 Feb 6. PMID: 23389291; PMCID: PMC3670254. (* co-corresponding authors)
20: Zhou H*, Liu W*, Su Y, Wei Z, Liu J, Kolluri SK, Wu H, Cao Y, Chen J, Wu Y, Yan T, Cao X, Gao W, Molotkov A, Jiang F, Li WG, Lin B, Zhang HP, Yu J, Luo SP, Zeng JZ, Duester G, Huang PQ, Zhang XK. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 2010 Jun 15;17(6):560-73. doi: 10.1016/j.ccr.2010.04.023. PMID: 20541701; PMCID: PMC2907921. (* co-first authors)
21: Zhang L*, Zhou H*, Su Y*, Sun Z, Zhang H, Zhang L, Zhang Y, Ning Y, Chen YG, Meng A. Zebrafish Dpr2 inhibits mesoderm induction by promoting degradation of nodal receptors. Science. 2004 Oct 1;306(5693):114-7. doi: 10.1126/science.1100569. PMID: 15459392. (* co-first authors)
招聘：本实验室诚招助理教授，博士后，博士及硕士研究生。
联系方式: 电话: 0592-2881105（办）0592-2881106 (实) 电子邮箱： huzhou@xmu.edu.cn
